ArticleFrontiers in immunology2024
An effective strategy with tofacitinib for the management of focal myositis with rheumatoid arthritis: a case report.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxidative stress and inflammation: roles in osteoporosis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal myositis is a rare, localized, benign, self-limiting, and non-suppurative inflammatory lesion of the skeletal muscle that may occasionally occur as a complication of rheumatic diseases. This case report discusses a 58-year-old patient with rheumatoid arthritis, who was diagnosed with focal myositis during standard immunosuppressive therapy. The patient was treated with tofacitinib; to our knowledge, this is the first reported case of focal myositis managed with this medication. Clinicians should maintain a suspicion for focal myositis in patients presenting with localized muscle swelling and pain, especially those with underlying rheumatic conditions. In cases where corticosteroid tapering proves difficult, tofacitinib may be considered as an alternative therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.